Elanco Animal Health Incorporated
NYSE:ELANDrug Manufacturers - Specialty & Generic
-$0.84 today
- Market cap
- $13.35B
- Beta
- 1.70
- P/E (TTM)
- -48.1
- EPS (TTM)
- -$0.49
Volume 5.78M
Average 6.04M
ELAN Other Stockholders Equity
Equity items not reported separately, such as additional paid-in capital or treasury stock.
Elanco Animal Health IncorporatedNYSE: ELAN
Other Stockholders Equity · Q3 FY2026 · quarter ended Sep 2026
Other stockholders equity remains negative
Q3 FY2026 other stockholders equity was $8.9B, compared with $0 a year earlier.
Context
- Other stockholders equity amounted to 66.7% of total assets at the end of Q3 FY2026, up 66.7 pp from a year earlier.
- Other stockholders equity increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Stockholders Equity history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Other Stockholders Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Stockholders Equity vs competitors
How ELAN compares with its peers on the latest reported figures
- ELAN's Sep 2026 other stockholders equity of $8.9B is the highest of the 6 companies compared; the peer median is $0.
- Other stockholders equity amounts to 66.7% of total assets for ELAN, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $8.9B | — | — | 66.7% | |
| Sep 2026 | $1.87B | +29907.7% | +5.6% | 50.4% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Aug 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ELAN) | $0 | +29907.7% | +5.6% | 0.0% | |
Competitors are the stored peer set for ELAN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 638M | 345M | 352M | 468M | 545M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.03B | 1B | 1.01B | 886M | 940M |
| Inventory | 1.37B | 1.54B | 1.74B | 1.57B | 1.74B |
| Other Current Assets | 0 | 394M | 310M | 287M | 236M |
| Total Current Assets | 3.27B | 3.28B | 3.41B | 3.22B | 3.46B |
| Property, Plant & Equipment (Net) | 1.06B | 999M | 1.03B | 993M | 1.41B |
| Goodwill | 6.17B | 5.99B | 5.09B | 4.41B | 4.78B |
| Intangible Assets | 5.59B | 4.84B | 4.49B | 3.68B | 3.41B |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 390M | 378M | 341M | 311M | 304M |
| Total Non-current Assets | 13.2B | 12.21B | 10.96B | 9.4B | 9.9B |
| Total Assets | 16.48B | 15.49B | 14.36B | 12.61B | 13.36B |
| Account Payables | 416M | 390M | 270M | 296M | 368M |
| Short-term Debt | 294M | 388M | 38M | 44M | 74M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 937M | 924M | 933M | 975M | 1.16B |
| Total Current Liabilities | 1.65B | 1.7B | 1.24B | 1.32B | 1.6B |
| Long-term Debt | 6.03B | 5.45B | 5.74B | 4.28B | 3.94B |
| Deferred Tax Liabilities | 765M | 662M | 567M | 449M | 382M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 533M | 390M | 595M | 477M | 889M |
| Total Non-current Liabilities | 7.32B | 6.5B | 6.9B | 5.2B | 5.21B |
| Total Liabilities | 8.97B | 8.2B | 8.14B | 6.52B | 6.81B |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | (979M) | (1.06B) | (2.29B) | (1.95B) | (2.18B) |
| Accumulated OCI | (209M) | (392M) | (266M) | (771M) | (141M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 7.51B | 7.29B | 6.22B | 6.1B | 6.55B |
| Total Debt | 6.32B | 5.84B | 5.77B | 4.32B | 4.02B |
| Net Debt | 5.68B | 5.49B | 5.42B | 3.85B | 3.47B |
Elanco Animal Health Incorporated
NYSE:ELAN
Intrinsic Alpha fair value
Locked
Current Price
$26.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.